Opthea Limited (ASX:OPT)
Australia · Delayed Price · Currency is AUD | Market Cap | 738.77M +61.5% |
| Revenue (ttm) | -20.12K -43.3% |
| Net Income | 296.97M |
| EPS | 0.23 |
| Shares Out | 1.23B |
| PE Ratio | 2.59 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,141,489 |
| Average Volume | 5,974,614 |
| Open | 0.6050 |
| Previous Close | 0.6000 |
| Day's Range | 0.5950 - 0.6150 |
| 52-Week Range | 0.3350 - 1.1650 |
| Beta | 1.50 |
| RSI | 21.86 |
| Earnings Date | May 29, 2026 |
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ... [Read more]
Financial Performance
In fiscal year 2025, Opthea's revenue was 222,694, a decrease of -43.29% compared to the previous year's 392,686. Losses were -248.31 million, -24.78% less than in 2024.
Financial StatementsNews
Opthea Transcript: AGM 2025
The AGM covered director re-elections, adoption of the remuneration report, and approval of option grants, with all resolutions put to a poll and no questions raised by shareholders. Voting results will be published post-meeting.
Opthea Transcript: Investor Update
Phase III trials failed to show efficacy for sozinibercept in wet AMD, leading to program termination and a settlement with investors that leaves the company with $20 million cash and no debt. A strategic review is underway to explore internal and external opportunities, with updates expected later this year.
Opthea Provides Corporate Update
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to contin...
Opthea terminates COAST trial, announces ShORe trial misses endpoint
Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its second Phase 3 trial ShORe in patients with wet…
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Opthea downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Opthea (OPT) to Perform from Outperform.
Opthea downgraded to Market Perform from Outperform at Leerink
Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform.
Opthea cut to Market Perform at Leerink on failed sozinibercept trial
Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company announcing that its Phase 3 COAST trial…
Opthea double downgraded to Underperform from Buy at Jefferies
Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8, after the company announced that its Eylea combo trial failed to meet…
Opthea downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield downgraded Opthea (OPT) to Neutral from Buy with a price target of $2, down from $12 after the Phase 3 COAST Eylea combo trial failed…
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors
Opthea (OPT) announced results from its global Phase 3 clinical trial COAST in patients with wet AMD. The global COAST Phase 3 trial evaluated the efficacy and safety of intravitreally…
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
Opthea Ltd (ADR) trading halted, news pending
10:07 EDT Opthea (OPT) Ltd (ADR) trading halted, news pending
Opthea announces Phase 2b Wet AMD publication
Opthea (OPT) announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina. The paper entitled “Sozinibercept Combination Therapy ...
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
Reports 1H revenue $149,000 vs. $202,000 last year. “Opthea (OPT) is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live…
Opthea announces anticipated milestones
Phase 3 topline results from COAST, expected in early Q2 CY2025; Phase 3 topline results from ShORe, expected in mid-CY2025; BLA submission in 1H CY2026
Opthea completes drug product PPQ campaign
Opthea (OPT) announced the completion of its drug product Process Performance Qualification campaign for sozinibercept. The PPQ campaign consisted of the successful production of three consecutive com...
Opthea completes COAST final week 52 patient visit
Opthea (OPT) has completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with…
Opthea Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Sozinibercept, a VEGF-C/D trap, is advancing through Phase 3 trials for wet AMD, targeting improved vision outcomes in combination with anti-VEGF-A agents. Pivotal data readouts are imminent, with strong market, payer, and physician support, and a potential FDA approval by late 2026.
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Opthea Wet AMD Data Featured at Macula Society Meeting
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Transcript: Investor Day 2025
Sozinibrecept is positioned as a first-in-class combination therapy for wet AMD, with pivotal phase 3 data expected in 2024 and potential FDA approval by end of 2026. The product targets a $7B+ U.S. market, offers robust clinical differentiation, and is supported by a strong commercial team and favorable payer feedback.
Opthea Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Sozinibercept, a first-in-class VEGF-C/D trap, has shown superior vision outcomes in wet AMD and is in two pivotal Phase III trials with top-line data expected in 2024. The company is well-funded, targeting a 2026 BLA submission, and preparing for a U.S. launch.
Opthea to host investor days in New York, Australia
Opthea (OPT) will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February.